Search

Displaying results 361 - 370 of 495 in total
  1. Target

    Basement membrane-specific heparan sulfate proteoglycan core protein

    go.drugbank.com/bio_entities/BE0001031
    TargetHumans

    Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It se...

    Polypeptides: Basement membrane-specific heparan sulfate proteoglycan core protein
  2. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Also known as baptitoxine or sophorine, cytisine has been used as a smoking cessation treatment since 1964, and is relatively unknown in regions outside of central and Eastern Europe.

  3. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L39030] This indication is valid in the US, Europe, and Canada. … [A187985] Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects.

  4. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Reslizumab is marketed as Cinqaero in Europe. … randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to the first attack compared

  5. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    Mifamurtide is marketed in Europe as Mepact for intravenous infusion.

  6. Indication

    Ariboflavinosis

    go.drugbank.com/conditions/DBCOND0020583
    Drugs: Riboflavin
    Synonyms: Vitamin deficiency: [B-complex deficiency NOS] or [ariboflavinosis] or [B12 nutritional deficiency NOS]
  7. Indication

    Menkes Disease

    go.drugbank.com/conditions/DBCOND0042586
    Drugs: Copper histidinate
    Synonyms: Copper transport disease, X-linked copper deficiency
  8. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier … The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization.

    Categories: Complex Mixtures
  9. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.

  10. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex